United States Cancer Vaccines Market to Reach $4.48 Billion by 203 | Preventive cancer vaccines hold 58% share, driven by HPV and HBV vaccine adoption

Leander, Texas and Tokyo, Japan - Dec.03.2025
As per DataM intelligence research report" The global cancer vaccines market reached US$ 8.82 Billion in 2023, with a rise of US$ 9.27 Billion in 2024 and is expected to reach US$ 14.96 Billion by 2033, growing at a CAGR of 5.5% during the forecast period 2025-2033." Advances in immunotherapy and personalized oncology are driving rapid innovation in cancer vaccine development.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/cancer-vaccines-market?Prasad

United States: Recent Industry Developments

✅ In October 2025, Moderna released promising Phase 2 data for its mRNA-4359 cancer vaccine at the ESMO Congress The vaccine showed a 24% objective response rate in patients with advanced solid tumors when combined with immunotherapy It validates Moderna's strategic pivot toward oncology as a primary growth driver in the U.S.

✅ In September 2025, Merck initiated a large-scale Phase 3 trial for its collaborative personalized cancer vaccine with Moderna The trial targets adjuvant treatment in patients with resected high-risk stage II melanoma It represents a major step toward the first commercial approval of a personalized mRNA cancer vaccine

✅ In August 2025, The FDA granted Breakthrough Therapy Designation to a new neoantigen-based cancer vaccine candidate from Daiichi Sankyo The designation expedites the development of personalized treatments for high-risk melanoma patients It signals strong regulatory support for mRNA-based oncological therapies in the U.S.

✅ In July 2025, researchers at a major U.S. cancer center published results on an "off-the-shelf" vaccine for pancreatic cancer The study demonstrated that the vaccine could induce a robust T-cell response in early-stage patients It offers new hope for treating one of the deadliest forms of cancer in the U.S.

Japan: Recent Industry Developments

✅ In November 2025, BioNTech expanded its strategic partnership with Japanese pharma companies to co-develop mRNA cancer immunotherapies The collaboration focuses on conducting clinical trials for novel cancer vaccines within the Japanese population It aims to accelerate the introduction of "Individualized Neoantigen Specific Immunotherapy" to Japan

✅ In October 2025, Daiichi Sankyo announced the progression of its own ADC-based therapeutic vaccine pipeline The company is combining its antibody-drug conjugates with immune-boosting agents to enhance tumor recognition It leverages Japan's leadership in ADC technology to create next-generation cancer treatments

✅ In September 2025, The National Cancer Center Japan launched a nationwide registry for cancer vaccine clinical trials The initiative aims to match patients with suitable experimental vaccine therapies across the country It improves patient access to cutting-edge immunotherapy research in Japan

✅ In August 2025, NEC Corporation utilized its AI drug discovery platform to identify new neoantigens for a head and neck cancer vaccine The AI-driven approach significantly shortens the lead time for vaccine design and personalization It showcases the integration of Japanese IT expertise with biopharmaceutical innovation

Cancer Vaccines Market: Drivers
The cancer vaccines market is growing as advancements in immunotherapy and precision medicine reshape cancer prevention and treatment strategies. Therapeutic and prophylactic vaccines are designed to trigger targeted immune responses against tumor-specific antigens, improving patient outcomes and reducing recurrence risk. Rising investment in oncology R&D, biomarker discovery, and personalized vaccine platforms is driving innovation. Technological progress in neoantigen discovery, mRNA vaccines, and viral vector-based delivery is enhancing efficacy and safety. Additionally, increasing awareness of early detection and preventive healthcare is supporting market adoption.

Collaboration among biotech firms, research institutions, and pharmaceutical companies is accelerating clinical development and regulatory approvals for cancer vaccines. Growth in combination therapies, checkpoint inhibitors, and immune modulation approaches is broadening therapeutic potential. Expansion of clinical trials and genomic profiling programs is enabling more personalized treatment pathways. With rising cancer incidence, scientific breakthroughs, and increasing global healthcare investment, the cancer vaccines market is poised for strong long-term growth.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/cancer-vaccines-market?Prasad

Cancer Vaccines Market: Major Players
Merck & Co., Inc., GlaxoSmithKline plc (GSK), and Dendreon Pharmaceuticals LLC, among others.

Segment Covered in the Cancer Vaccines Market:
By Type
Preventive cancer vaccines hold 58% share, driven by HPV and HBV vaccine adoption and strong government immunization programs. Therapeutic cancer vaccines account for 42%, supported by rising clinical trials, personalized oncology approaches, and growing demand for immune-modulating therapies.

By Cancer Type
Cervical cancer leads with 32% share, driven by global HPV vaccination programs. Prostate cancer accounts for 21%, while lung cancer holds 18% with increasing development of therapeutic vaccine candidates. Bladder cancer contributes 12%, and other cancers make up the remaining 17%.

By Technology
Protein-based vaccines dominate with 35% share, favored for safety and stability. Nucleic acid-based (DNA/RNA) solutions account for 27%, accelerated by mRNA advancements. Viral vector vaccines hold 16%, dendritic cell vaccines 12%, whole-cell vaccines 7%, and recombinant/adjuvant platforms the remaining 3%.

By Route of Administration
Intramuscular administration leads with 64% share, driven by ease of dosing and strong use in preventive vaccines. Intravenous delivery holds 23%, mainly for therapeutic cancer vaccines requiring targeted immune activation. Other routes contribute 13%, including subcutaneous and intradermal approaches.

By End User
Hospitals dominate with 41% share, given their central role in oncology treatment and immunization delivery. Cancer treatment centers hold 29%, supported by rising adoption of individualized vaccine therapies. Clinics account for 18%, while government and public health entities represent 7%. Other users contribute 5%.

Regional Analysis
North America - 39%
North America leads with 39% share, driven by strong R&D, widespread HPV vaccination, and rapid adoption of therapeutic cancer vaccine innovations.

Europe - 27%
Europe holds 27%, supported by robust immunization programs, favorable regulatory pathways, and expanding cancer vaccine trials.

Asia-Pacific - 26%
Asia-Pacific captures 26%, fueled by government-backed vaccination drives, growing cancer burden, and increased biopharma investments.

South America - 4%
South America accounts for 4%, led by improving vaccine infrastructure and rising HPV/HBV vaccine uptake.

Middle East & Africa - 4%
Middle East & Africa hold 4%, driven by gradual expansion of preventive vaccination programs and improving healthcare access.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=cancer-vaccines-market
(Purchase 2 or more Repots and get 50% Discount)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?Prasad

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.